BioAge Labs (NASDAQ:BIOA) Announces Quarterly Earnings Results

BioAge Labs (NASDAQ:BIOA) posted its earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, FiscalAI reports. The business had revenue of $3.08 million for the quarter.

BioAge Labs Stock Performance

Shares of BIOA stock opened at $16.11 on Wednesday. The firm has a market cap of $577.54 million, a P/E ratio of -10.60 and a beta of 1.22. The firm’s 50 day moving average price is $20.20 and its 200-day moving average price is $12.84. BioAge Labs has a one year low of $2.88 and a one year high of $24.00.

Analyst Ratings Changes

BIOA has been the topic of several analyst reports. Citigroup lifted their price target on shares of BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Piper Sandler began coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Morgan Stanley set a $23.00 target price on BioAge Labs in a research report on Wednesday, February 4th. Finally, Oppenheimer initiated coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

Insider Buying and Selling at BioAge Labs

In other news, insider Paul D. Rubin sold 7,433 shares of BioAge Labs stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the sale, the chief executive officer owned 976,949 shares in the company, valued at $17,702,315.88. This represents a 19.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 267,540 shares of company stock valued at $4,895,168 over the last quarter. 20.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of BioAge Labs in the second quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new position in shares of BioAge Labs in the second quarter valued at approximately $60,000. Jefferies Financial Group Inc. acquired a new position in shares of BioAge Labs in the second quarter valued at approximately $206,000. Finally, Stonepine Capital Management LLC increased its stake in BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after buying an additional 101,085 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.